Cancers, Vol. 12, Pages 229: RASSF1A Tumour Suppressor: Target the Network for Effective Cancer Therapy

Cancers, Vol. 12, Pages 229: RASSF1A Tumour Suppressor: Target the Network for Effective Cancer Therapy Cancers doi: 10.3390/cancers12010229 Authors: Lucía García-Gutiérrez Stephanie McKenna Walter Kolch David Matallanas The RASSF1A tumour suppressor is a scaffold protein that is involved in cell signalling. Increasing evidence shows that this protein sits at the crossroad of a complex signalling network, which includes key regulators of cellular homeostasis, such as Ras, MST2/Hippo, p53, and death receptor pathways. The loss of expression of RASSF1A is one of the most common events in solid tumours and is usually caused by gene silencing through DNA methylation. Thus, re-expression of RASSF1A or therapeutic targeting of effector modules of its complex signalling network, is a promising avenue for treating several tumour types. Here, we review the main modules of the RASSF1A signalling network and the evidence for the effects of network deregulation in different cancer types. In particular, we summarise the epigenetic mechanism that mediates RASSF1A promoter methylation and the Hippo and RAF1 signalling modules. Finally, we discuss different strategies that are described for re-establishing RASSF1A function and how a multitargeting pathway approach selecting druggable nodes in this network could lead to new cancer treatments.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research